Avadel, Jazz Pharmaceuticals End Patent Dispute With Settlement

Dow Jones

Oct 22, 2025

By Connor Hart

Avadel Pharmaceuticals and Jazz Pharmaceuticals have reached a global settlement, ending years of litigation over patent rights tied to their respective narcolepsy treatments.

Under the agreement, both companies will dismiss their lawsuits with prejudice, preventing the claims from being brought to court again.

Avadel will pay Jazz an ongoing 3.85% royalty on net sales of Lumryz for narcolepsy, beginning Oct. 1, 2025, through Feb. 18, 2036. In turn, Jazz will pay Avadel $90 million and waive its right to receive royalties or damages on past sales of the drug.

The settlement also prevents Lumryz from being sold for any other indication before March 1, 2028. If Avadel receives future FDA approval for a new indication, those sales will carry a 10% royalty through Feb. 18, 2036.

The agreement also grants each company broad patent protections, bringing long-term clarity to their respective oxybate sleep disorder therapies.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

October 22, 2025 07:07 ET (11:07 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2577365696"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577365696\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577365696?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-22 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577365696","market":"us","top_or_hot":-1,"title":"Avadel, Jazz Pharmaceuticals End Patent Dispute With Settlement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Avadel Pharmaceuticals and Jazz Pharmaceuticals have reached a global settlement, ending years of litigation over patent rights tied to their respective narcolepsy treatments. \n</p>\n<p>\n  Under the agreement, both companies will dismiss their lawsuits with prejudice, preventing the claims from being brought to court again. \n</p>\n<p>\n  Avadel will pay Jazz an ongoing 3.85% royalty on net sales of Lumryz for narcolepsy, beginning Oct. 1, 2025, through Feb. 18, 2036. In turn, Jazz will pay Avadel $90 million and waive its right to receive royalties or damages on past sales of the drug. \n</p>\n<p>\n  The settlement also prevents Lumryz from being sold for any other indication before March 1, 2028. If Avadel receives future FDA approval for a new indication, those sales will carry a 10% royalty through Feb. 18, 2036. \n</p>\n<p>\n  The agreement also grants each company broad patent protections, bringing long-term clarity to their respective oxybate sleep disorder therapies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 22, 2025 07:07 ET (11:07 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avadel, Jazz Pharmaceuticals End Patent Dispute With Settlement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvadel, Jazz Pharmaceuticals End Patent Dispute With Settlement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-22 19:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Avadel Pharmaceuticals and Jazz Pharmaceuticals have reached a global settlement, ending years of litigation over patent rights tied to their respective narcolepsy treatments. \n</p>\n<p>\n  Under the agreement, both companies will dismiss their lawsuits with prejudice, preventing the claims from being brought to court again. \n</p>\n<p>\n  Avadel will pay Jazz an ongoing 3.85% royalty on net sales of Lumryz for narcolepsy, beginning Oct. 1, 2025, through Feb. 18, 2036. In turn, Jazz will pay Avadel $90 million and waive its right to receive royalties or damages on past sales of the drug. \n</p>\n<p>\n  The settlement also prevents Lumryz from being sold for any other indication before March 1, 2028. If Avadel receives future FDA approval for a new indication, those sales will carry a 10% royalty through Feb. 18, 2036. \n</p>\n<p>\n  The agreement also grants each company broad patent protections, bringing long-term clarity to their respective oxybate sleep disorder therapies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 22, 2025 07:07 ET (11:07 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0823416689.USD","symbol_name":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2577365696","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577365696","pubTimestamp":1761131220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Avadel Pharmaceuticals and Jazz Pharmaceuticals have reached a global settlement, ending years of litigation over patent rights tied to their respective narcolepsy treatments.Under the agreement, both companies will dismiss their lawsuits with prejudice, preventing the claims from being brought to court again.Avadel will pay Jazz an ongoing 3.85% royalty on net sales of Lumryz for narcolepsy, beginning Oct. 1, 2025, through Feb. 18, 2036. In turn, Jazz will pay Avadel $90 million and waive its right to receive royalties or damages on past sales of the drug.The settlement also prevents Lumryz from being sold for any other indication before March 1, 2028. If Avadel receives future FDA approval for a new indication, those sales will carry a 10% royalty through Feb. 18, 2036.The agreement also grants each company broad patent protections, bringing long-term clarity to their respective oxybate sleep disorder therapies.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4532":"文艺复兴科技持仓","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","AVDL":"Avadel Pharmaceuticals plc","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4007":"制药","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","JAZZ":"爵士制药","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC"},"translate_title":"Avadel与Jazz Pharmaceuticals达成和解结束专利纠纷","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVDL":0.9,"JAZZ":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Avadel Pharmaceuticals and Jazz Pharmaceuticals have reached a global settlement, ending years of litigation over patent rights tied to their respective narcolepsy treatments. \n\n\n  Under the agreement, both companies will dismiss their lawsuits with prejudice, preventing the claims from being brought to court again. \n\n\n  Avadel will pay Jazz an ongoing 3.85% royalty on net sales of Lumryz for narcolepsy, beginning Oct. 1, 2025, through Feb. 18, 2036. In turn, Jazz will pay Avadel $90 million and waive its right to receive royalties or damages on past sales of the drug. \n\n\n  The settlement also prevents Lumryz from being sold for any other indication before March 1, 2028. If Avadel receives future FDA approval for a new indication, those sales will carry a 10% royalty through Feb. 18, 2036. \n\n\n  The agreement also grants each company broad patent protections, bringing long-term clarity to their respective oxybate sleep disorder therapies. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 22, 2025 07:07 ET (11:07 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}